These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22648001)

  • 41. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanism of FGF23 processing in fibrous dysplasia.
    Bhattacharyya N; Wiench M; Dumitrescu C; Connolly BM; Bugge TH; Patel HV; Gafni RI; Cherman N; Cho M; Hager GL; Collins MT
    J Bone Miner Res; 2012 May; 27(5):1132-41. PubMed ID: 22247037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibroblast growth factor 23 and acute kidney injury.
    Neyra JA; Moe OW; Hu MC
    Pediatr Nephrol; 2015 Nov; 30(11):1909-18. PubMed ID: 25480729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.
    David V; Martin A; Isakova T; Spaulding C; Qi L; Ramirez V; Zumbrennen-Bullough KB; Sun CC; Lin HY; Babitt JL; Wolf M
    Kidney Int; 2016 Jan; 89(1):135-46. PubMed ID: 26535997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
    de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
    Sato T; Muroya K; Asakura Y; Yachie A; Nishimura G; Aida N; Machida J; Tanaka Y; Hasegawa T; Adachi M
    Am J Med Genet A; 2015 Oct; 167A(10):2430-4. PubMed ID: 26059403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
    Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M; Santos-Araújo C; Poínhos R; Oliveira B; Silva IS; Silva LS; Sousa MJ; Correia F; Pestana M
    Clin Nephrol; 2016 Mar; 85(3):135-41. PubMed ID: 26833300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period.
    Takaiwa M; Aya K; Miyai T; Hasegawa K; Yokoyama M; Kondo Y; Kodani N; Seino Y; Tanaka H; Morishima T
    Bone; 2010 Aug; 47(2):256-62. PubMed ID: 20641162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome.
    Hanudel MR; Zinter MS; Chen L; Gala K; Lim M; Guglielmo M; Deshmukh T; Vangala S; Matthay M; Sapru A
    PLoS One; 2019; 14(9):e0222065. PubMed ID: 31487315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease?
    Masi L; Franceschelli F; Leoncini G; Gozzini A; Rigante D; La Torre F; Matucci-Cerinic M; Brandi ML; Falcini F
    Clin Exp Rheumatol; 2013; 31(1):149-53. PubMed ID: 23324126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
    Farrow EG; Yu X; Summers LJ; Davis SI; Fleet JC; Allen MR; Robling AG; Stayrook KR; Jideonwo V; Magers MJ; Garringer HJ; Vidal R; Chan RJ; Goodwin CB; Hui SL; Peacock M; White KE
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):E1146-55. PubMed ID: 22006328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
    Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
    Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of a new automated chemiluminescence immunoassay for FGF23.
    Shimizu Y; Fukumoto S; Fujita T
    J Bone Miner Metab; 2012 Mar; 30(2):217-21. PubMed ID: 21898178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
    Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
    Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic accuracy of fibroblast growth factor 23 for predicting acute kidney injury in patients with acute decompensated heart failure.
    Pramong N; Gojaseni P; Suttipongkeat S; Kiattisunthorn K; Chittinandana A
    Nephrology (Carlton); 2021 Feb; 26(2):126-133. PubMed ID: 32902010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
    Fukumoto S
    Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy.
    Gardner J; Ashraf A; You Z; McCormick K
    J Pediatr Endocrinol Metab; 2011; 24(9-10):645-50. PubMed ID: 22145450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.